TerminatedNot Applicable

A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)

Stopped: Sponsor decision to terminate; sufficient sample size for statistical analysis has been achieved.

Argentina, Australia321 participantsStarted 2023-03-14

Plain-language summary

A prospective cohort study utilizing biospecimen sample collection from adult Hemophilia A subjects to evaluate and characterize seroprevalence and the seroconversion of antibodies against AAV serotypes

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult Subjects with Hemophilia A Exclusion Criteria: * Subject previously treated with AAV vector gene therapy

What they're measuring

To qunatify Seroprevalence of antibodies to selected AAV serotypes

Timeframe: 52 weeks

Trial details

NCT IDNCT05580692

SponsorBioMarin Pharmaceutical

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-07-31

View on ClinicalTrials.gov More Hemophilia A trials